Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
230 participants
INTERVENTIONAL
2013-09-01
2017-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxycodone/naloxone prolonged release tablets
Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
Oxycodone/naloxone prolonged release tablets
Oxycodone prolonged release tablets
Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks
Oxycodone/naloxone prolonged release tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxycodone/naloxone prolonged release tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of musculo-skeletal pain for 4 weeks or longer with non-malignant pain etiology at Visit 1. Possible etiologies are conditions related to intervertebral disc disease, spondylolisthesis and osteoarthritis; other similar non-malignant diseases are also eligible.
* Patients with non-malignant pain that require around-the-clock opioid therapy (oxycodone equivalent of ≥10 mg/day and ≤50 mg/day) who are likely to benefit from WHO step III opioid therapy for the duration of the study
* Patients who have been already treated with NSAIDs at least 2 weeks before enrolment are also eligible, but they should rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as ≥4 on 0-10 scale."
* Subjects are either taking opioid medication or willing to take opioids to treat their pain
* Patients who are willing to use adequate and reliable contraception throughout the study. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilization, implants, injectable, combined oral contraceptives, some IUDs (intrauterine Device, hormonal), sexual abstinence or vasectomized partner
* Subjects willing and able to participate in all aspects of the study, including use of oral medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements are evidenced by providing written informed consent
* Subjects taking pre-study, non-opioid analgesics, and all other concomitant medications, including those medications for the treatment of depression and are considered necessary for the subject's welfare, and are anticipated to remain stable throughout the double-blind period of the study, and are to be continued under the supervision of the investigator, are eligible.
* Patients who have been already treated with NSAIDs at least 2 weeks before enrolment are also eligible, but they should rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as ≥4 on 0-10 scale.
Criteria for entry to the Double-Blind phase:
1. Subjects continue to satisfy screening criteria outlined in the protocol
2. Subject's OXY dose is between 10-50 mg/day
3. Subjects who rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as≤4 on 0-10 scale with less than or equal to two doses of Morphine Sulfate tablets rescue medication per day for either the last three consecutive days or four of the last seven days
4. Subjects who have constipation induced, or worsened by their opioid study medication, as shown by:
1. The subject's medical need for regular intake of laxatives to have at least 3 bowel evacuations per week, or having less than 3 bowel evacuations per week when not taking a laxative, respectively and
2. The subjects' constipation was considered to be induced, worsened or maintained by their current study opioid medication and
3. BFI value \> 30.
5. Subjects demonstrate compliance with laxative use, and completing appropriate and legible daily diaries
6. Subjects taking daily fibre supplementation or bulking agents are eligible if they can be maintained on a stable dose and regimen throughout the study, and in the investigator's opinion are willing and able to maintain adequate hydration.
Exclusion Criteria
2. Any history of hypersensitivity or with any contraindication to oxycodone, naloxone, bisacodyl, or related products
3. Subjects currently taking the equivalent of \> 50 mg/day Oxycodone PR
4. Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal (paralytic ileus), or psychiatric disease, as determined by medical history, clinical laboratory tests, electrocardiogram (ECG) results, and physical examination, that will place the subject at risk upon exposure to the study medication or that could confound the analysis and/or interpretation of the study results
5. Subjects with evidence of impaired liver/kidney function upon entry into the study defined as aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels \>3 times the upper limit of normal; gamma glutamyltranspeptidase (GGT or GGTP) ≥ 5 times the upper limit of normal; total bilirubin level outside of the reference range; and/or creatinine level outside of the reference range or \>2 mg/dl, or in the investigator's opinion, liver and/or kidney impairment to the extent that the subject should not participate in this study
6. Subjects with evidence of significant structural abnormalities of the gastrointestinal tract or any diseases/conditions that affect bowel transit
7. Subjects who have required treatment for the diagnosis of irritable bowel syndrome (IBS)
8. Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the investigator's opinion, may pose a risk of additional CNS depression with opioids study medication
9. Surgery within 2 months prior to the start of the Screening Period, or planned surgery during the 12-week Double-blind Phase that may have affected GI motility or pain
10. Subjects diagnosed with cancer, not including basal cell carcinoma
11. Subjects with Rheumatoid Arthritis (RA)
12. Subjects receiving opioid substitution therapy for opioid addiction (e.g., methadone or buprenorphine)
13. Subjects with active alcohol or drug abuse and/or history of opioid abuse
14. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period)
15. Subjects presently taking, or who had taken naloxone or naltrexone within 30 days of study entry (defined as the start of the Screening Period).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mundipharma (China) Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Victoria Yu
Role: STUDY_DIRECTOR
Mundipharma, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
Second Affiliated Hospital of Shan Tou University Medical College
Shantou, Guangdong, China
Hebei General Hospital
Shijiazhuang, Hebei, China
Beijing friendship hospital
Beijing, , China
Beijing Tiantan Hospital
Beijing, , China
Beijing Union hospital
Beijing, , China
Peking Union Medical College Hospital
Beijing, , China
Peking University Third Hospital
Beijing, , China
The first affiliated hospital of Bengbu medical collage
Bengbu, , China
The third Xiangya hospital of central south university
Changsha, , China
The thrid Xiangya Hospital of central south university
Changsha, , China
Xiangya hospital central south university
Changsha, , China
West China Hospital
Chengdu, , China
Daping Hospital
Chongqing, , China
South West hospital
Chongqing, , China
Fuzhou general hospital
Fuzhou, , China
The third affiliated hospital Sun yat-sen university
Guangzhou, , China
Guizhou Provincial People's Hospital
Guizhou, , China
The second affiliated hospital of Harbin medical university
Harbin, , China
Shandong Provincial Hospital
Jinan, , China
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, , China
Shanghai Changhai Hospital
Shanghai, , China
Shanghai Sixth People's Hospital
Shanghai, , China
Zhongshan Hospital Fudan University
Shanghai, , China
The first affiliated hospital of Shantou university medical college
Shantou, , China
The general hospital of Shenyang military
Shenyang, , China
The central hospital of Wuhan
Wuhan, , China
Tongji Hospital
Wuhan, , China
Union Hospital Tongji medical college
Wuhan, , China
The affiliated hospital of Xuzhou medical university
Xuzhou, , China
Second affiliated hospital of Zhejiang university
Zhejiang, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Leng X, Zhang F, Yao S, Weng X, Lu K, Chen G, Huang M, Huang Y, Zeng X, Hopp M, Lu G. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial. Adv Ther. 2020 Mar;37(3):1188-1202. doi: 10.1007/s12325-020-01244-x. Epub 2020 Feb 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OXN08-CN-302a
Identifier Type: -
Identifier Source: org_study_id